Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1979;8(Suppl 1):7S–13S. doi: 10.1111/j.1365-2125.1979.tb00449.x

Pharmacokinetics and metabolism of various benzodiazepines used as hypnotics

D D Breimer
PMCID: PMC1429621  PMID: 41545

Abstract

1 In the management of insomnia with drugs, any action should be restricted to the duration of the night and residual effects should be absent during the day-time. The intermittent type of drug action desired is fundamentally different from drug treatment where a constant effect is sought.

2 Duration of drug action is dependent on the kinetics of distribution and elimination of the parent drug and its effective metabolites. In addition biopharmaceutical factors, such as those which promote a rapid rate of absorption, are important.

3 These considerations serve as a guide for a review of the kinetics and metabolism of various benzodiazepines.

Full text

PDF
7S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beyer K. H., Sadée W. Spektrophotometrische Bestimmung von 5-Phenyl-1,4-benzodiazepin-Derivaten und Untersuchungen über den des Nitrazepams. 5. Chemie und Analytik von Benzodiazepin-Derivaten. Arzneimittelforschung. 1969 Dec;19(12):1929–1931. [PubMed] [Google Scholar]
  2. Bixler E. O., Kales A., Soldatos C. R., Kales J. D. Flunitrazepam, an investigational hypnotic drug: sleep laboratory evaluations. J Clin Pharmacol. 1977 Oct;17(10 Pt 1):569–578. doi: 10.1177/009127007701701004. [DOI] [PubMed] [Google Scholar]
  3. Breimer D. D. Clinical pharmacokinetics of hypnotics. Clin Pharmacokinet. 1977 Mar-Apr;2(2):93–109. doi: 10.2165/00003088-197702020-00002. [DOI] [PubMed] [Google Scholar]
  4. Cano J. P., Soliva M., Hartmann D., Ziegler W. H., Amrein R. Bioavailability from various galenic formulations of flunitrazepam. Arzneimittelforschung. 1977;27(12):2383–2388. [PubMed] [Google Scholar]
  5. Eatman F. B., Colburn W. A., Boxenbaum H. G., Posmanter H. N., Weinfeld R. E., Ronfeld R., Weissman L., Moore J. D., Gibaldi M., Kaplan S. A. Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects. J Pharmacokinet Biopharm. 1977 Oct;5(5):481–494. doi: 10.1007/BF01061729. [DOI] [PubMed] [Google Scholar]
  6. Fuccella L. M., Bolcioni G., Tamassia V., Ferrario L., Tognoni G. Human pharmacokinetics and bioavailability of temazepam administered in soft gelatin capsules. Eur J Clin Pharmacol. 1977 Dec 16;12(5):383–386. doi: 10.1007/BF00562455. [DOI] [PubMed] [Google Scholar]
  7. Greenblatt D. J., Joyce T. H., Comer W. H., Knowles J. A., Shader R. I., Kyriakopoulos A. A., MacLaughlin D. S., Ruelius H. W. Clinical pharmacokinetics of lorazepam. II. Intramuscular injection. Clin Pharmacol Ther. 1977 Feb;21(2):222–230. doi: 10.1002/cpt1977212222. [DOI] [PubMed] [Google Scholar]
  8. Kales A., Bixler E. O., Scharf M., Kales J. D. Sleep laboratory studies of flurazepam: a model for evaluating hypnotic drugs. Clin Pharmacol Ther. 1976 May;19(5 Pt 1):576–583. doi: 10.1002/cpt1976195part1576. [DOI] [PubMed] [Google Scholar]
  9. Kangas L. Comparison of two gas-liquid chromatographic methods for the determination of nitrazepam in plasma. J Chromatogr. 1977 Jun 11;136(2):259–270. doi: 10.1016/s0021-9673(00)86278-0. [DOI] [PubMed] [Google Scholar]
  10. Kangas L., Kanto J., Syvälahti E. Plasma nitrazepam concentrations after an acute intake and their correlation to sedation and serum growth hormone levels. Acta Pharmacol Toxicol (Copenh) 1977 Jul;41(1):65–73. doi: 10.1111/j.1600-0773.1977.tb02124.x. [DOI] [PubMed] [Google Scholar]
  11. Kaplan S. A., de Silva J. A., Jack M. L., Alexander K., Strojny N., Weinfeld R. E., Puglisi C. V., Weissman L. Blood level profile in man following chronic oral administration of flurazepam hydrochloride. J Pharm Sci. 1973 Dec;62(12):1932–1935. doi: 10.1002/jps.2600621205. [DOI] [PubMed] [Google Scholar]
  12. Karim A. K., Evans D. A. Polymorphic acetylation of nitrazepam. J Med Genet. 1976 Feb;13(1):17–19. doi: 10.1136/jmg.13.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Klotz U., Avant G. R., Hoyumpa A., Schenker S., Wilkinson G. R. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975 Feb;55(2):347–359. doi: 10.1172/JCI107938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Korttila K., Kangas L. Unchanged protein binding and the increase of serum diazepam levels after food intake. Acta Pharmacol Toxicol (Copenh) 1977 Feb;40(2):241–246. doi: 10.1111/j.1600-0773.1977.tb02074.x. [DOI] [PubMed] [Google Scholar]
  15. Mandelli M., Tognoni G., Garattini S. Clinical pharmacokinetics of diazepam. Clin Pharmacokinet. 1978 Jan-Feb;3(1):72–91. doi: 10.2165/00003088-197803010-00005. [DOI] [PubMed] [Google Scholar]
  16. Post C., Lindgren S., Bertler A., Malmgren H. Pharmacokinetics of N-desmethyldiazepam in healthy volunteers after single daily doses of dipotassium chlorazepate. Psychopharmacology (Berl) 1977 Jul 18;53(2):105–109. doi: 10.1007/BF00426477. [DOI] [PubMed] [Google Scholar]
  17. Rieder J. Plasma levels and derived pharmacokinetic characteristics of unchanged nitrazepam in man. Arzneimittelforschung. 1973 Feb;23(2):212–218. [PubMed] [Google Scholar]
  18. de Boer A. G., Röst-Kaiser J., Bracht H., Breimer D. D. Assay of underivatized intrazepam and clonazepam in plasma by capillary gas chromatography applied to pharmacokinetic and bioavailability studies in humans. J Chromatogr. 1978 Jan 1;145(1):105–114. doi: 10.1016/s0378-4347(00)81672-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES